e-learning
resources
Berlin 2001
Monday 24.09.2001
DOTS in action
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Population of bacteria in treatment of patients with tuberculosis by DOTS method
G. R. Minassian, M. D. Safaryan (Yerevan, Armenia)
Source:
Annual Congress 2001 - DOTS in action
Session:
DOTS in action
Session type:
Oral Presentation
Number:
1248
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. R. Minassian, M. D. Safaryan (Yerevan, Armenia). Population of bacteria in treatment of patients with tuberculosis by DOTS method. Eur Respir J 2001; 16: Suppl. 31, 1248
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Results of the treatment of relapses of tuberculosis by DOTS method
Source: Eur Respir J 2001; 18: Suppl. 33, 339s
Year: 2001
Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia)
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015
Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany
Source: International Congress 2016 – Update on drug-resistant tuberculosis
Year: 2016
Surgical treatment for MDR TB patients – preliminary results from a Romanian MDR TB centre
Source: Eur Respir J 2006; 28: Suppl. 50, 276s
Year: 2006
Linezolid in the treatment of patients with MDR TB and XDR TB
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Spread of tuberculosis among household contacts of multi drug resistant tuberculosis (MDRTB) patients
Source: International Congress 2014 – Tuberculosis: epidemiology and public health
Year: 2014
Implementation of rapid drug-susceptibility testing for patients at high risk of multidrug-resistant tuberculosis in Cambodia
Source: Annual Congress 2013 –Diagnostic features of tuberculosis I
Year: 2013
Outcomes of DOTS and DOTS Plus regimens implementing among patients with pulmonary tuberculosis relapses
Source: Eur Respir J 2002; 20: Suppl. 38, 369s
Year: 2002
Management of multidrug-resistant tuberculosis and patients in retreatment
Source: Eur Respir J 2005; 25: 928-936
Year: 2005
Outcomes of individualized treatment for MDR TB in Iran
Source: Annual Congress 2007 - Medical and surgical treatment of susceptible and resistant tuberculosis
Year: 2007
Gene-Xpert for rapid detection of MDR-TB in re-treatment cases;a comparison with standard culture and DST
Source: International Congress 2015 – WHO guidelines in TB and clinical practice
Year: 2015
Prospects for early implementation of ambulatory treatment in XDR TB patients by optimizing the administration of linezolid at the intensive phase of chemotherapy
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
MDR-TB treatment outcomes in HIV positive patients
Source: International Congress 2014 – Tuberculosis: from diagnosis to therapy and prevention
Year: 2014
Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB)
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
Drug resistance in previously treated patients of tuberculosis in pre DOTS and DOTS era and its implications
Source: Annual Congress 2009 - Tuberculosis control
Year: 2009
A multicentric cohort analysis of culture conversion and reversion in multidrug resistant tuberculosis (MDRTB) patients
Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights
Year: 2013
A novel nurse-led approach improves treatment completion rates for latent tuberculosis infection (LTBI) treatment
Source: International Congress 2014 – Mycobacterium tuberculosis infection: new therapeutic approaches
Year: 2014
Treatment results in patients with XDR tuberculosis in Ukraine
Source: Eur Respir J 2007; 30: Suppl. 51, 272s
Year: 2007
Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept